2019年

by 腫瘍病態学分野
  1. Kanemaru Y, Natsumeda M, Okada M, Saito R, Kobayashi D, Eda T, Watanabe J, Saito S, Tsukamoto Y, Oishi M, Saito H, Nagahashi M, Sasaki T, Hashizume R, Aoyama H, Wakai T, Kakita A, Fujii Y. Dramatic response of BRAFV600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. Acta Neuropathol Commun. 7(1):119, 2019.
  2. Watanabe J, Natsumeda M, Kanemaru Y, Okada M, Oishi M, Kakita A, Fujii Y. Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma. Leuk Lymphoma, 60(14):3587-3589, 2019.
  3. Watanabe J, Natsumeda M, Okada M, Kanemaru Y, Tsukamoto Y, Oishi M, Kakita A, Fujii Y. Podoplanin expression and IDH-wildtype status predict venous thromboembolism in patients with high-grade gliomas in the early postoperative period. World Neurosurg, 128:e982-e988, 2019.
  4. Watanabe J, Okamoto K, Ohashi T, Natsumeda M, Hasegawa H, Oishi M, Miyatake S, Matsumoto N, Fujii Y. Malignant hyperthermia and cerebral venous sinus thrombosis after ventriculoperitoneal shunt in infant with schizencephaly and COL4A1 mutation. World Neurosurg, 127:446-450, 2019.
  5. Watanabe J, Natsumeda M, Okada M, Kobayashi D, Kanemaru Y, Tsukamoto Y, Oishi M, Kakita A, Fujii Y. High detection rate of MYD88 mutations in cerebrospinal fluid from patients with CNS lymphomas. JCO Precis Oncol, 2019. 
  6. Ota T, Natsumeda M, Yoshida S, Tsukamoto Y, Watanabe J, Kanemaru Y, Ando K, Yoshida Y, Hiraishi T, Okamoto K, Nagahashi M, Wakai T, Kakita A, Oishi M, Fujii Y. A dramatic, transient effect of nivolumab combined with whole-brain irradiation for the treatment of primary meningeal melanomatosis. Clin Case Rep Rev, 5:3-4, 2019.
  7. Nozawa T, Okada M, Natsumeda M, Eda T, Abe H, Tsukamoto Y, Okamoto K, Oishi M, Takahashi H, Fujii Y, Kakita A. EGFRvIII is expressed in cellular areas of tumor in a subset of glioblastoma. Neurol Med Chir (Tokyo), 59(3):89-97, 2019.
  8. 平石哲也、棗田学、岡田正康、大石誠、藤井幸彦． 悪性髄膜腫における個別化医療の可能性．Precision Medicine2(1):54-58, 2019. (和)
  9. Natsumeda M, Liu Y, Nakata S, Miyahara H, Hanaford A, Ahsan S, Stearns D, Skuli N, Raabe EH, Rodriguez FJ, Eberhart CG. Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high-MYC medulloblastoma. Neuropathology, 39(2):71-77, 2019.